metformin has been researched along with Adenocarcinoma, Follicular in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 7.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Metformin is a widely used drug to treat patients with type II diabetes." | 5.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 3.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Metformin is a widely used drug to treat patients with type II diabetes." | 1.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| "Metformin inhibits thyroid cancer cell growth." | 1.42 | Glucose-deprivation increases thyroid cancer cells sensitivity to metformin. ( Bikas, A; Boyle, L; Burman, KD; Costello, J; Hoperia, V; Jensen, K; Klubo-Gwiezdzinska, J; Larin, O; McDaniel, D; Patel, A; Vasko, V; Wartofsky, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mousavi, Z | 1 |
| Dourandish, L | 1 |
| Rokni, H | 1 |
| Sadeghi, R | 1 |
| Rasoul Zakavi, S | 1 |
| Bikas, A | 1 |
| Jensen, K | 1 |
| Patel, A | 1 |
| Costello, J | 1 |
| McDaniel, D | 1 |
| Klubo-Gwiezdzinska, J | 1 |
| Larin, O | 1 |
| Hoperia, V | 1 |
| Burman, KD | 1 |
| Boyle, L | 1 |
| Wartofsky, L | 1 |
| Vasko, V | 1 |
| Park, J | 1 |
| Kim, WG | 1 |
| Zhao, L | 1 |
| Enomoto, K | 1 |
| Willingham, M | 1 |
| Cheng, SY | 1 |
| Chen, G | 1 |
| Xu, S | 1 |
| Renko, K | 1 |
| Derwahl, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study[NCT04298684] | Phase 4 | 90 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for metformin and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Body Weight; Carcinoma, Papillary; Dose-Response Relationship, Dr | 2014 |
3 other studies available for metformin and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
Glucose-deprivation increases thyroid cancer cells sensitivity to metformin.
Topics: Adenocarcinoma, Follicular; AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Papillary; Carrier | 2015 |
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.
Topics: Adenocarcinoma, Follicular; Anaplasia; Animals; Antineoplastic Agents; Cell Proliferation; Diet, Hig | 2016 |
Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell D | 2012 |